Akeso, Inc.
9926
Xếp hạng trong cổ phiếu
#1934
Akeso, Inc. is a biopharmaceutical enterprise dedicated to the discovery,... Akeso, Inc. is a biopharmaceutical enterprise dedicated to the discovery, development, manufacturing, and commercialization of therapeutic solutions. The company boasts a diverse pipeline, with a significant focus on oncology. Its cancer-focused treatments include AK104, a PD-1/CTLA-4 bi-specific antibody in development for various malignancies such as cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and other solid tumors. Another bi-specific antibody, AK112, targets PD-1/VEGF and is being developed for solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). Akeso also has several monoclonal antibodies in its oncology portfolio: AK105, a PD-1 monoclonal antibody, is aimed at NSCLC, NPC, relapsed/refractory classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma, thymic cancer, esophageal squamous cell carcinoma (ESCC), urothelial carcinoma (UC), GC, GEJ, cholangiocarcinoma, neuroendocrine tumors, and mismatch repair deficient solid tumors. AK117, a CD47 monoclonal antibody, is being investigated for myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, head and neck squamous cell carcinoma (HNSCC), R/R cHL, NPC, NSCLC, as well as general solid tumors and lymphomas. AK119, a CD73 monoclonal antibody, is under development for solid tumors. AK109, a VEGFR-2 monoclonal antibody, targets solid tumors and gastric cancer. Beyond oncology, Akeso is developing treatments for immunological and metabolic conditions: AK120, an IL-4R monoclonal antibody, for moderate-to-severe atopic dermatitis, asthma, and eosinophilic esophagitis. AK101, an IL-12/IL-23 monoclonal antibody, for moderate-to-severe psoriasis and ulcerative colitis. AK111, an IL-17 monoclonal antibody, for moderate-to-severe psoriasis and ankylosing spondylitis. AK102, a PCSK9 monoclonal antibody, designed to treat hypercholesterolemia. Its preclinical pipeline features AK127, a TIGIT monoclonal antibody for solid tumors, and AK115, an NGF monoclonal antibody. Akeso, Inc. collaborates with key partners including Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and the MD Anderson Medical Institute. The company was established in 2012 and operates from its headquarters in Zhongshan, People's Republic of China.
Giá cổ phiếu
$11.83
Vốn hóa thị trường
$10.89B
Thay đổi (1 ngày)
1.15%
Thay đổi (1 năm)
-23.08%
Quốc gia
CN
Giao dịch Akeso, Inc. (9926)
Danh mục
Healthcare
Thu nhập của Akeso, Inc. (9926)
Thu nhập trong Jun 2026 TTM: $-142.22M
Theo báo cáo tài chính gần đây của Akeso, Inc., lợi nhuận hiện tại của công ty là $-142.22M. Năm 2023, công ty đạt được lợi nhuận là $274.42M, tăng so với lợi nhuận năm 2022 là $-206.18M. Lợi nhuận hiển thị trên trang này là lợi nhuận trước lãi vay và thuế, hay còn gọi là EBIT.
Lịch sử thu nhập của Akeso, Inc. từ 2018 đến 2026
Thu nhập vào cuối mỗi năm
| Năm | Thu nhập | Thay đổi |
|---|---|---|
| 2026 (TTM) | $-142.22M | 107.17% |
| 2024 | $-68.65M | -125.02% |
| 2023 | $274.42M | -233.10% |
| 2022 | $-206.18M | 4.16% |
| 2021 | $-197.95M | -2.08% |
| 2020 | $-202.15M | 306.29% |
| 2019 | $-49.75M | 121.72% |
| 2018 | $-22.44M | 0.00% |
Thu nhập của các công ty hoặc đối thủ tương tự
| Công ty | Thu nhập | Chênh lệch thu nhập | Quốc gia |
|---|---|---|---|
| $5.27B | -3,808.85% |
US
|
|
| $-3.09B | 2,070.51% |
US
|
|
| $-4.02B | 2,723.84% |
AU
|
|
| $1.95B | -1,471.53% |
NL
|
|
| - | - |
CH
|
